Loading...

ALTS ALT5 SIGMA CORP Company Mergers 8-K Filing

LT5

LTS

ALT5 SIGMA CORP

(ALTS)

2025 8-K

Compliance Update

Annual Meeting Results

Governance Update

Board Appointment

Director Appointment

Loan Agreement Signed

CFO Appointment

Annual Meeting Notice

Accounting Changes

Litigation Settlement

New Accountant Appointment

Board Resignation Notification

Accountant Resignation

Management Changes

Financial Reporting Delay

Consultant Lawsuit

Share Increase Approval

Token Use Waivers

Special Stockholder Meeting

Recent Developments

Management Changes

Share Offering Details

Asset Acquisitions

Financial Statements

Financial Results

Annual Meeting Results

Acquisition Proposal

Q3 Financial Results

CEO Appointment

Agreement for Stock Offering

Merger of Equals

Settlement Agreement with SEC

Merger of Equals

Securities Purchase Agreement

Delisting Compliance Regained

Unit Purchase Agreements

Amendment of Promissory Obl...

Amendment of Promissory Obl...

Agreement with Investor

Annual Meeting of Stockholders

Delisting Notice

Securities Purchase Agreement

Change in Certifying Accoun...

Restatement of Financial St...

External Links:

On May 21, 2025, ALT5 Sigma Corp announced the upcoming separation of its healthcare assets, Alyea Therapeutics Corp, with June 2, 2025 as the record date for the transaction, and detailed key management appointments including Dr. Amol Soin as the prospective CEO.

AI Assistant

ALT5 SIGMA CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.